Rita Frangiamore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rita Frangiamore has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Renato Mantegazza
Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy
5 shared publications - Carlo Antozzi
Immunotherapy and Apheresis Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
4 shared publications - Fiammetta Vanoli
Neuroimmunology and Neuromuscular Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
3 shared publications - Lorenzo Maggi
Neuroimmunology and Neuromuscular Disease Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
3 shared publications - Elena Rinaldi
Neurology 4–Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
2 shared publications - Francesca Andreetta
Neuroimmunology and Neuromuscular Disease Unit, Foundation IRCCS Carlo Besta Neurological Institute, Milan, Italy
2 shared publications
Latest Publications
- 21 May 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (6)
Disease changes and cost analysis of myasthenia gravis: a 10 years retrospective study from a reference center in Italy
Objective study was the quantification of controlled/inadequately controlled generalized myasthenia gravis (gMG) disease burden, health care resource utilization and costs in MG patients, followed-up at a reference center for MG in Italy. The study is a 2010 to 2020 retrospective analysis of gMG patients. Clinical and health economics variables were those observed during routine clinical care. Data were anonymized and treated in aggregated forms in compliance with GDPR. Only patients with gMG were included in the study. Out of 237 patients, 55.3% were males and 44.7% females with a median follow up duration of 4.7 years. Males were older, with a median age at onset of 58.3 years versus 45.7 years for females; an increased representation of late and very late onset patients was recorded. A shorter time from onset to diagnosis was observed in males. The incidence rate per year of exacerbations changed from 0.76 in the first year to 0.23 at the sixth year, with a similar trend for MG crisis; both exacerbations and crisis incidence were higher in inadequately controlled patients. Disease burden and health care resources utilizations were particularly evident in inadequately controlled patients, which showed a 138% increase of costs. Our data confirmed the observed epidemiological changes occurring in MG population and the high use of health care system resources in uncontrolled patients. The estimates obtained will provide a useful basis for assessing the impact of recently introduced targeted therapies on healthcare expenditure for MG.
- 21 May 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (6)
Disease changes and cost analysis of myasthenia gravis: a 10 years retrospective study from a reference center in Italy
Objective study was the quantification of controlled/inadequately controlled generalized myasthenia gravis (gMG) disease burden, health care resource utilization and costs in MG patients, followed-up at a reference center for MG in Italy. The study is a 2010 to 2020 retrospective analysis of gMG patients. Clinical and health economics variables were those observed during routine clinical care. Data were anonymized and treated in aggregated forms in compliance with GDPR. Only patients with gMG were included in the study. Out of 237 patients, 55.3% were males and 44.7% females with a median follow up duration of 4.7 years. Males were older, with a median age at onset of 58.3 years versus 45.7 years for females; an increased representation of late and very late onset patients was recorded. A shorter time from onset to diagnosis was observed in males. The incidence rate per year of exacerbations changed from 0.76 in the first year to 0.23 at the sixth year, with a similar trend for MG crisis; both exacerbations and crisis incidence were higher in inadequately controlled patients. Disease burden and health care resources utilizations were particularly evident in inadequately controlled patients, which showed a 138% increase of costs. Our data confirmed the observed epidemiological changes occurring in MG population and the high use of health care system resources in uncontrolled patients. The estimates obtained will provide a useful basis for assessing the impact of recently introduced targeted therapies on healthcare expenditure for MG.
- 6 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (1) , 111
Does myasthenia gravis impact cognitive functioning? A systematic review and meta-analysis
Background Myasthenia Gravis, traditionally known as a purely motor disease, has been recently associated also with non-motor symptoms, including psychological and cognitive symptoms. However, the presence of cognitive impairment in Myasthenia Gravis remains unclear due to limited and heterogeneous findings. This systematic review and meta-analysis aims to clarify the relationship between Myasthenia Gravis and cognitive performances. Methods Following PRISMA guidelines, we systematically searched PubMed, Web of Science, and SCOPUS for original researches published between January 2000 and December 2024 assessing cognitive functioning in people with MG compared to healthy controls. Pooled standardized mean differences and 95% confidence intervals were calculated for each cognitive domain using random-effects meta-analysis. Results Six studies comprising 242 Myasthenia Gravis patients and 166 healthy controls met inclusion criteria. Compared to healthy controls, people with Myasthenia Gravis showed significantly lower performance in processing speed (Symbol Digit Modalities Test), phonemic and animal verbal fluency, visuo-spatial memory (visual reproduction), and verbal learning (California Verbal Learning Test). Heterogeneity was low to moderate across most outcomes. Conclusions This meta-analysis supports the presence of selective cognitive impairments in individuals with Myasthenia Gravis. These findings underscore the need for a multidimensional approach to care in Myasthenia Gravis, that includes cognitive and psychological health.
- 6 January 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (1) , 111
Does myasthenia gravis impact cognitive functioning? A systematic review and meta-analysis
Background Myasthenia Gravis, traditionally known as a purely motor disease, has been recently associated also with non-motor symptoms, including psychological and cognitive symptoms. However, the presence of cognitive impairment in Myasthenia Gravis remains unclear due to limited and heterogeneous findings. This systematic review and meta-analysis aims to clarify the relationship between Myasthenia Gravis and cognitive performances. Methods Following PRISMA guidelines, we systematically searched PubMed, Web of Science, and SCOPUS for original researches published between January 2000 and December 2024 assessing cognitive functioning in people with MG compared to healthy controls. Pooled standardized mean differences and 95% confidence intervals were calculated for each cognitive domain using random-effects meta-analysis. Results Six studies comprising 242 Myasthenia Gravis patients and 166 healthy controls met inclusion criteria. Compared to healthy controls, people with Myasthenia Gravis showed significantly lower performance in processing speed (Symbol Digit Modalities Test), phonemic and animal verbal fluency, visuo-spatial memory (visual reproduction), and verbal learning (California Verbal Learning Test). Heterogeneity was low to moderate across most outcomes. Conclusions This meta-analysis supports the presence of selective cognitive impairments in individuals with Myasthenia Gravis. These findings underscore the need for a multidimensional approach to care in Myasthenia Gravis, that includes cognitive and psychological health.
- 25 March 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (7) , 3271-3279
Efgartigimod improves non-AChR generalized Myasthenia Gravis: a real world experience
Introduction The neonatal Fc receptor (FcRn) inhibitor Efgartigimod (EFG) has been approved for treatment of generalized Myasthenia Gravis (gMG) with anti-AChR antibodies. Information on the effect of EFG in non-AChR MG is limited. We investigated the efficacy of EFG in non-AChR gMG along a clinical follow-up of 2 years. Methods We treated 13 patients with gMG without anti-AChR antibodies: 5 MuSK+, 2 LRP4 + and 6 triple-negative (confirmed by live CBA). EFG was administered according to the GENERATIVE protocol (consisting of a Fixed period of 2 treatment cycles of 4 infusions at weekly intervals, followed by a Flexible period during which EFG was given in case of initial worsening) starting from November 2021. Outcomes were evaluated by means of the MG-ADL, QMG, MGC and MGQoL15r scales. Results The mean follow-up was 21 ± 5.3 months. Meaningful improvement was observed with the clinical scores adopted. The number of cycles/year was 3.92 ± 0.9. The interval between cycles was 10.1 ± 3.6 weeks. MG-ADL improvement of at least 5 points was recorded in 58% of cycles. 46% of patients required hospitalization during the two years before treament with EFG and 70% plasmaexchange/IVIG; during EFG none of the patients was hospitalized or required immunomodulation. No major side effects or infusion related reactions occurred. Conclusion EFG was effective in non-AChR gMG and modified significantly the course of the disease. Our experience strengthens the role of FcRn inhibition as a new therapeutic tool for MG without anti-AChR antibodies.
- 25 March 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (7) , 3271-3279
Efgartigimod improves non-AChR generalized Myasthenia Gravis: a real world experience
Introduction The neonatal Fc receptor (FcRn) inhibitor Efgartigimod (EFG) has been approved for treatment of generalized Myasthenia Gravis (gMG) with anti-AChR antibodies. Information on the effect of EFG in non-AChR MG is limited. We investigated the efficacy of EFG in non-AChR gMG along a clinical follow-up of 2 years. Methods We treated 13 patients with gMG without anti-AChR antibodies: 5 MuSK+, 2 LRP4 + and 6 triple-negative (confirmed by live CBA). EFG was administered according to the GENERATIVE protocol (consisting of a Fixed period of 2 treatment cycles of 4 infusions at weekly intervals, followed by a Flexible period during which EFG was given in case of initial worsening) starting from November 2021. Outcomes were evaluated by means of the MG-ADL, QMG, MGC and MGQoL15r scales. Results The mean follow-up was 21 ± 5.3 months. Meaningful improvement was observed with the clinical scores adopted. The number of cycles/year was 3.92 ± 0.9. The interval between cycles was 10.1 ± 3.6 weeks. MG-ADL improvement of at least 5 points was recorded in 58% of cycles. 46% of patients required hospitalization during the two years before treament with EFG and 70% plasmaexchange/IVIG; during EFG none of the patients was hospitalized or required immunomodulation. No major side effects or infusion related reactions occurred. Conclusion EFG was effective in non-AChR gMG and modified significantly the course of the disease. Our experience strengthens the role of FcRn inhibition as a new therapeutic tool for MG without anti-AChR antibodies.
- 24 October 2023
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (3) , 1307-1309
Efgartigimod improves triple-negative myasthenia gravis
- 24 October 2023
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (3) , 1307-1309
Efgartigimod improves triple-negative myasthenia gravis
- Open Access
- 5 May 2023
- Published by Wiley in Muscle & Nerve
- Vol. 68 (1) , 65-72
Concordance between patient‐ and physician‐reported Myasthenia Gravis Activities of Daily Living (MG‐ADL) scores
Introduction/Aims: Myasthenia gravis (MG) is a neuromuscular disease characterized by abnormal skeletal muscle fatiguability. The MG Activities of Daily Living (MG‐ADL) scale assesses eight symptoms and is often used as primary endpoint in MG clinical trials where it is completed by neurologists. However, in observational studies, patients frequently complete the MG‐ADL scale independently of their neurologist. In this study we aimed to assess the concordance between self‐ and physician‐reported MG‐ADL scores.Methods: An international observational study was conducted among adult patients with MG scheduled for a routine visit or who entered the hospital via emergency services. Consenting patients and physicians completed the MG‐ADL. Concordance between assessments was calculated using Gwet's agreement coefficient (Gwet's AC) for the MG‐ADL individual items and the intraclass correlation coefficient (ICC) for the MG‐ADL total score.Results: Data were collected from 137 patients (63% female; mean age, 57.7 years). Physicians assessed the patient's symptoms as slightly more severe (8.1 vs 7.5 MG‐ADL total score, respectively), corresponding to a difference of 0.6 on a range from 0 to 24. The ICC for the MG‐ADL total score between the patient and the physician assessment was 0.94 (95% confidence interval, 0.89 to 0.95), showing excellent concordance. Gwet's AC showed substantial to almost perfect agreement for all items, except eyelid droop, for which the agreement was moderate.Discussion: Our results demonstrate that patients and neurologists have a concordant assessment of the patient's MG symptoms when using the MG‐ADL scale. This evidence supports patient self‐administration of the MG‐ADL in clinical practice and research.
- 5 May 2023
- Published by Wiley in Muscle & Nerve
- Vol. 68 (1) , 65-72
Open AccessConcordance between patient‐ and physician‐reported Myasthenia Gravis Activities of Daily Living (MG‐ADL) scores
Introduction/Aims: Myasthenia gravis (MG) is a neuromuscular disease characterized by abnormal skeletal muscle fatiguability. The MG Activities of Daily Living (MG‐ADL) scale assesses eight symptoms and is often used as primary endpoint in MG clinical trials where it is completed by neurologists. However, in observational studies, patients frequently complete the MG‐ADL scale independently of their neurologist. In this study we aimed to assess the concordance between self‐ and physician‐reported MG‐ADL scores.Methods: An international observational study was conducted among adult patients with MG scheduled for a routine visit or who entered the hospital via emergency services. Consenting patients and physicians completed the MG‐ADL. Concordance between assessments was calculated using Gwet's agreement coefficient (Gwet's AC) for the MG‐ADL individual items and the intraclass correlation coefficient (ICC) for the MG‐ADL total score.Results: Data were collected from 137 patients (63% female; mean age, 57.7 years). Physicians assessed the patient's symptoms as slightly more severe (8.1 vs 7.5 MG‐ADL total score, respectively), corresponding to a difference of 0.6 on a range from 0 to 24. The ICC for the MG‐ADL total score between the patient and the physician assessment was 0.94 (95% confidence interval, 0.89 to 0.95), showing excellent concordance. Gwet's AC showed substantial to almost perfect agreement for all items, except eyelid droop, for which the agreement was moderate.Discussion: Our results demonstrate that patients and neurologists have a concordant assessment of the patient's MG symptoms when using the MG‐ADL scale. This evidence supports patient self‐administration of the MG‐ADL in clinical practice and research.